© Genesis Research Services, 2023
Menu
Knee osteoarthritis can develop over a short period of time, although it is usually a slower process resulting in considerable damage to the joints, which can lead to deformity or disability. The main symptoms may include pain, stiffness, creaking, crunching, grinding sensation during knee movement, lumps or deformities, and/or swelling.
We are looking for people living with knee osteoarthritis to join our new clinical trial. Ongoing treatment with the investigational product will be provided throughout the study. This will be at no cost to you, and you will be reimbursed for your participation.
View our trials page for more information.
Knee osteoarthritis is characterised by bone changes, progressive loss of cartilage, joint space narrowing, and even total joint failure. It causes pain, physical disability, and reduced quality of life. Current treatments include medications, creams, gels, and injections.
We frequently conduct trials involving treatments for osteoarthritis of the knee. Treatments may include oral medications, topical treatments, or injections.
To register your interest for future studies, visit our trials page.
Low back pain is one of the most common types of pain reported by patients and the leading cause of disability worldwide.
We conduct numerous trials for people living with low back pain. Trials may involve injections or medical devices such as spinal cord stimulators. Medical costs are typically covered (no private health insurance is required).
To register your interest for future studies, visit our trials page.
We have the highest number of enrollments to date for a clinical trial involving an investigational medical device for people living chronic back and/or leg pain.
Enrollment for this study is now closed, however, if you would like to be notified about future studies for low back pain, you can register your interest here.
We were also one of the top five recruiters for a clinical trial evaluating an investigational vaccine for Respiratory Syncytial Virus (RSV).
We recruited over 60 participants for the study and successfully completed all participant final visits.
Our coordinators did an amazing job recruiting participants for a study involving a potential new treatment for osteoarthritis of the knee. We exceeded our recruitment target by 13%.
Enrollment for this study is now closed, however, we are currently recruiting participants for another knee OA study. View our trials page for more information.
The numbers for 2022 are in. Here’s what we achieved this year:
Emily is our newest Clinical Trial Coordinator. She is a highly experienced Registered Nurse with over 16 years of perioperative nursing experience. Originally from the UK, she moved to Sydney in 2012 and relocated to Newcastle in 2018.
Emily is passionate about finding new treatment options through clinical research, and has a keen interest in chronic back, neuropathic, and cancer related pain. She also enjoys teaching and educating, and the holistic care approach that can be offered to trial participants.
Caitlin joins the Genesis team as a Research Administrative Assistant and is excited to put her customer service skills to use to help patients with their health and wellbeing. She is currently completing a Certificate IV in Nutrition and is passionate about further upskilling her knowledge in health and wellness.
Caitlin has a strong desire to help others and is driven to help make a difference in helping patients with potential new treatments.
Back in September, we said farewell to Mohamad, one of our Clinical Trial Coordinators, as he left us to begin a new chapter in his life.
Mo was a critical member of our clinical team and coordinated several high volume clinical trials for Genesis.
During our final day working with Mo, we enjoyed a staff day out and attempted an escape room. Unfortunately, we failed to escape from Alcatraz… (We were so close!)
We wish Mo the best of luck with everything and miss his positive personality in the office every day!
In August, our trial coordinator Heather attended the Neuromodulation Society of Australia and New Zealand (NSANZ) annual scientific meeting in Melbourne. The meeting featured numerous esteemed international and national guest speakers. It consisted of breakout sessions, scientific posters, social networking events, and more.
Heather learnt so much about the future of neuromodulation and hopes that we will be able to be involved in those future research opportunities. She enjoyed catching up with people from some of the great companies that we work with and meeting some new faces.
Our research manager, Julia, recently attended the ARCS summit and dinner – “Get the D.I.R.T. on Digitalisation of Clinical Trials” held in Melbourne.
The summit focused on four key topics that need to be considered to prepare for decentralised trials, namely, digitalisation, main issues with implementation, risks and oversight, and technology.
Julia said the summit was very interesting and that it gave her a lot to think about when it comes to decentralized trials.
We recently released a new online training course: Research Fundamentals. The course provides a comprehensive introduction to key aspects of clinical trials and aims to break down complex concepts often encountered in the world of clinical research.
The course is intended for any clinical research professional, particularly those who are new to or looking to enter the industry, and those looking to expand or solidify their understanding of essential clinical trial concepts.
If you’ve visited our site lately, you may have met the friendly neighborhood cat.
We don’t know its name or where it lives. What we do know is that it enjoys sunbaking in our carpark and seems to want to come inside. (Unfortunately for the cat, we only don’t have any treats here, only treatments).
Please be mindful of the cat when driving into and out of the carpark and when entering and exiting the building.
The three-year results of the ReActiv8-B clinical trial have been published. Drs Russo and Volschenk are investigators on this ongoing trial.
ReActiv8 is an implanted neurostimulation system that activates the multifidus muscle in the lower spine (see picture). The study has shown that the device may provide long lasting improvements in pain and/or disability in people living with mechanical chronic low back pain associated with multifidus muscle weakness.
Dr Russo co-authored a review article on the effectiveness of Peripheral Nerve Field Stimulation (PNFS) for chronic low back pain and persistent spinal pain syndrome.
The review included data from 15 studies. The results suggested that PNFS may reduce back and leg pain and improve physical function, when used alone or in combination with spinal cord stimulation. However, we need more evidence to support this and to assess the long-term effectiveness.
A clinical trial is complete when the final participant’s last follow-up visit has occurred, and final data collection is complete. After this, the data are analysed and a final study report is written. This process can take several months. During this time, participants may be wondering, “What happens to me now?”. In this article, we answer the following questions:
View our currently recruiting studies:
Register your interest for future studies:
© Genesis Research Services, 2023